<DOC>
	<DOCNO>NCT02612480</DOCNO>
	<brief_summary>Rationale : In patient suffer myocardial infarction P2Y12 receptor antagonist prasugrel ticagrelor improve outcome prognosis compare clopidogrel . Moreover , ticagrelor lower mortality pulmonary infection sepsis , solely explain platelet-inhibiting effect . An effect inflammatory response set acute myocardial might underlie phenomenon substantiated support novel beneficial mechanism new P2Y12 receptor antagonist . Objective : To study whether ticagrelor , add acetylsalicylic acid , modulate inflammatory response administration lipopolysaccharide ( LPS ) humans vivo , compare effect P2Y12 antagonist clopidogrel . Study design : Prospective randomize placebo-controlled trial , accord PROBE design ( prospective randomize open blinded-endpoint study ) . Study population : Forty healthy male volunteer age ≥ 18 ≤ 35 year . Intervention ( applicable ) : Participants randomize receive either placebo ( twice daily ) , acetylsalicylic acid ( 80 mg daily , load dose 160 mg ) + placebo ( daily ) , acetylsalicylic acid ( 80 mg daily , load dose 160 mg ) + ticagrelor ( 90 mg twice daily , load dose 180 mg ) acetylsalicylic acid ( 80 mg daily , load dose 160 mg ) + clopidogrel ( 75 mg daily , load dose 300mg ) . Main study parameters/endpoints : Endpoints : area curve proinflammatory cytokine TNF-alpha , IL6 , IL-10 , IL1ra IL-8 , IL-1β , MCP-1 MIP-1a , MIP-1b en IFN ; peak concentration various cytokine ; plasma concentration HMGP1 ; platelet-monocyte complex formation marker platelet function ; plasma concentration adenosine .</brief_summary>
	<brief_title>Ticagrelor Human Endotoxemia Response Human Endotoxemia</brief_title>
	<detailed_description />
	<mesh_term>Endotoxemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Acetylsalicylic acid lysinate</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age ≥ 18 ≤ 35 year Male No known current medical/psychiatric disease History , sign symptoms cardiovascular disease History chronic obstructive pulmonary disease ( COPD ) asthma History hemorrhagic diathesis , disorder associate increase risk bleed Previous spontaneous vagal collapse Use medication Smoking Liver enzyme abnormality ( define ALAT and/or ASAT &gt; twice upper limit normality ) Thrombocytopenia ( &lt; 150*109 /ml ) anemia ( haemoglobin &lt; 8.0 mmol/L ) Any obvious disease associate immune deficiency Febrile illness week LPS challenge Hypersensitivity ticagrelor excipients Active pathological bleeding History intracranial haemorrhage History dyspepsia quantitative bleeding assessment tool ( BAT ) score &gt; 3 ( see Appendix 1 ) Participation another drug trial donation blood 3 month prior , 3 month plan LPS challenge Cardiac conduction abnormality ECG consist 2nd degree atrioventricular block , third degree atrioventricular block complex bundle branch block Hypertension ( define RR systolic &gt; 160 RR diastolic &gt; 90 ) Hypotension ( define RR systolic &lt; 100 RR diastolic &lt; 50 ) Renal impairment ( define MDRD &lt; 60 ml/min )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>endotoxin</keyword>
	<keyword>LPS</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>acetylsalicyclic acid</keyword>
	<keyword>placebo</keyword>
</DOC>